Bristol-myers Squibb Compnay

Angela Goodenough

Alan J Korman

Haichun Huang

Mohan Srinivasan

Nils Lonberg

Guodong Chen

Maria N Jure-Kunkel

Aaron Paul Yamniuk

Richard Y Huang

Karla Ann Henning

Martin J Corbett

Bryan C Barnhart

Ming Lei

John S Sack

Liang Schweizer

Sandra V Hatcher

Emanuela Sega

Joseph E Myers, Jr

Pingping Zhang

Joseph E Myers

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

Antibodies against CD73

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

Growing community of inventors

Morrisville, PA, United States of America

Angela Goodenough